Philips PHIA.AS
Philips is a health technology company that designs and manufactures diagnostic imaging equipment, patient monitoring, and connected health solutions, selling to both hospitals and consumers. Philips shows acceptable financial health (ND/EBITDA 2.35) and an attractive valuation (forward P/E 13.22, FCF yield 7.02%), but revenue growth is flat (0.50%) and the strong earnings growth (61.40%) may not be sustainable, which tempers optimism.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Philips is a health technology company that designs and manufactures diagnostic imaging equipment, patient monitoring, and connected health solutions, selling to both hospitals and consumers. Philips shows acceptable financial health (ND/EBITDA 2.35) and an attractive valuation (forward P/E 13.22, FCF yield 7.02%), but revenue growth is flat (0.50%) and the strong earnings growth (61.40%) may not be sustainable, which tempers optimism.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.9 |
| Quality / Moat | 6.2 |
| Valuation | 7.0 |
| Growth | 6.4 |
| Dividend | 7.0 |
| Momentum | 5.1 |
| Risk & Context | 6.7 |
OVERALL SCORE: 6.4/10
Context and risks
Country of domicile (Netherlands) with moderate governance/regulatory risk according to the assigned reference. Additionally, the medical devices sector is subject to active regulatory review (FDA, European MDR), adding a specific compliance risk.
News considered in the analysis
- European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading — Ruido de mercado sin información específica sobre la empresa.
- Is Koninklijke Philips (ENXTAM:PHIA) Below Fair Value As Lumea Draws Fresh Attention? — Artículo de análisis de valoración sin información nueva material.
- What is ASML? The company that makes chip-printing machines — Noticia sobre otra empresa (ASML), sin impacto directo en Philips.
- 1 Cash-Producing Stock to Research Further and 2 Facing Challenges — Listículo genérico sin información específica y verificable sobre Philips.
- 1 S&P 500 Stock with Exciting Potential and 2 We Ignore — Listículo genérico sin información específica y verificable sobre Philips.
Verdict: Hold; valuation is reasonable and the balance sheet is stable, but the lack of revenue growth and regulatory risk in the sector limit upside potential.
Main risk: The main risk is the regulatory exposure of the medical devices sector (FDA and European MDR), which can affect product approvals and generate compliance costs, along with the slow recovery of revenue growth.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →